Meliodays Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Meliodays Medical is an early-stage biotech innovator targeting the significant unmet need in menstrual health with its lead product, MelioOne®. This non-hormonal IUD is designed to deliver a sustained, low dose of the pain medication Celecoxib directly to the uterus over two years, aiming to reduce systemic exposure and side effects. The company, which closed an oversubscribed pre-seed round of over €800,000 in early 2025, is currently advancing the prototype through nonclinical development. Meliodays operates at the intersection of Medical Devices and Digital Health with a mission to address the gender health gap through research-backed solutions.

Women's HealthPain

Technology Platform

Drug-device combination platform utilizing an intrauterine device (IUD) form factor with a proprietary slow-release mechanism for localized, sustained delivery of pharmacological agents over extended periods (e.g., two years).

Opportunities

The company addresses a massive, underserved market of over 1.4 billion people with period pain, where current options are either short-acting (NSAIDs) or hormonal.

Success with MelioOne® could establish a new category of non-hormonal, long-acting gynecological therapeutics and provide a platform for treating other inflammatory conditions of the uterus.

Risk Factors

High technical risk associated with the novel, localized delivery of Celecoxib and the unproven efficacy/safety of this first-in-class combination product.

Significant financial risk as a pre-revenue startup with limited runway, requiring successful future fundraising.

Market adoption risk in convincing patients and clinicians to choose a procedural intervention over conventional pills.

Competitive Landscape

Competition primarily includes generic oral NSAIDs and hormonal therapies (pills, hormonal IUDs), which are entrenched but have significant limitations. There are no direct competitors offering a non-hormonal, long-acting intrauterine device specifically for pain relief, placing MelioOne® in a unique, if unvalidated, market niche.

More companies in Drug Delivery & Formulation →More companies in Germany →